October 17, 2025Osteoporosis InternationalOpen Access

Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study analyzes fracture incidence in breast cancer patients using endocrine therapy, suggesting age influences outcomes.

Patients aged over 50 show a reduced fracture risk with tamoxifen, while aromatase inhibitors increase risk in those under 50.
Fracture incidence was 12.6 per 1,000 person-years for those over 50, highlighting significant concerns after endocrine therapy.
Retrospective cohort study analyzed data from over 63,000 newly diagnosed breast cancer patients in South Korea from 2008 to 2016.
Long-term follow-up studies are warranted to better understand fracture risk in young breast cancer patients undergoing treatment.

Kwak et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

October 17, 2025Osteoporosis InternationalOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study analyzes fracture incidence in breast cancer patients using endocrine therapy, suggesting age influences outcomes.

Patients aged over 50 show a reduced fracture risk with tamoxifen, while aromatase inhibitors increase risk in those under 50.
Fracture incidence was 12.6 per 1,000 person-years for those over 50, highlighting significant concerns after endocrine therapy.
Retrospective cohort study analyzed data from over 63,000 newly diagnosed breast cancer patients in South Korea from 2008 to 2016.
Long-term follow-up studies are warranted to better understand fracture risk in young breast cancer patients undergoing treatment.

Kwak et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark